Another Losing Month for Biopharma

Several funds still made big bets on some major holdings.

Carsten Snejbjerg/Bloomberg

Carsten Snejbjerg/Bloomberg

After racing off to a strong start, most biopharma hedge funds posted a second straight month of sharp losses in March, a period in which many tech and other stocks posted healthy gains.

In fact, most of these funds fared worse than the NASDAQ Biotechnology Index, which was up 1.2

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.